Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRI-724 with mFOLFOX6/Bevacizumab in Metastatic Colorectal Cancer
NCT02413853Phase 2Withdrawn
- Sponsor
- University of Southern California
- Start
- Nov 2015
- Primary completion
- Nov 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of foscenvivint in metastatic colorectal cancer (mCRC), sponsored by University of Southern California. Planned start Nov 2015; status: withdrawn.
02
Drugs
foscenvivint
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT02413853.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02413853.